(1) Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, ZhangX and Zhang L. Epidemiological and clinical
characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (2020) 395: 507-13.
(2) Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson
BT, Wrigge H, Slutsky AS, Pesenti A, Investigators ftLS and Group tET. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA (2016) 315: 788-800.
(3) The World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. 2020. Available from: URL:
https://www. who.int/publications-detail/clinicalmanagementof-severe-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected.
(4) Colson P, Rolain JM, Lagier JC, Brouqui P and Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int. J. Antimicrob. Agents (2020) 2020: 105932.
(5) Sahraei Z, Shabani M, Shokouhi S and Saffaei A. Aminoquinolines against Coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int. J. Antimicrob. Agents (2020) 2020: 105945.
(6) Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, Aguilar G, Alba F, GonzálezHigueras E, Conesa LA, Martín-Rodríguez C, Díaz-Domínguez FJ, Serna-Grande P, Rivas R, Ferreres J, Belda J, Capilla L, Tallet A, Añón JM, Fernández RL, González-Martín JM, Aguilar G, Alba F, Álvarez J, Ambrós A, Añón JM, Asensio MJ, Belda J, Blanco J, Blasco M, Cachafeiro L, del Campo R, Capilla L, Carbonell JA, Carbonell N, Cariñena A, Carriedo D, Chico M, Conesa LA, Corpas R, Cuervo J, Díaz-Domínguez FJ, Domínguez-Antelo C, Fernández L, Fernández RL, Ferrando C, Ferreres J, Gamboa E, GonzálezHigueras E, González-Luengo RI, González-Martín JM, Martínez D, Martín-Rodríguez C, Muñoz T, Ortiz Díaz-Miguel R, Pérez-González R, Prieto AM, Prieto I, Rivas R, Rojas-Viguera L, Romera MA, Sánchez-Ballesteros J, Segura JM, Serna-Grande P, Serrano A, Solano R, Soler JA, Soro M, Tallet A and Villar J. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir. Med. (2020) 8: 267-76. 36 Jamaati HR et al. / IJPR (2020), 19 (1): 31-36
(7) Lee KY. Pneumonia, acute respiratory distress syndrome, and early immune-modulator therapy. Int. J. Mol. Sci. (2017) 18: E388.
(8) Pyrc K, Bosch BJ, Berkhout B, Jebbink MF, Dijkman R, Rottier P and van der Hoek L. Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob. Agents Chemother. (2006) 50: 2000-8.
(9) Henry BM. COVID-19, ECMO, and lymphopenia: a word of caution. Lancet Respir. Med. (2020) 2020: 1.